BACKGROUND/AIMS: To assess the outcomes and complications of endotamponade with Oxane HD following retinal detachment repair. METHODS: Retrospective consecutive case series of inferior retinal detachment with Oxane HD endotamponade within a 3-year period. RESULTS: Case notes for 18 eyes of 18 patients were reviewed. Four (22.2%) were total retinal detachments and 13 (72.2%) had proliferative vitreoretinopathy. The mean Oxane HD endotamponade and follow-up durations were 27 ± 38 and 66 ± 39 weeks, respectively. The eventual anatomic success rate was 77.8%, but without any significant difference in vision. Postoperative complications occurred in 14 (77.8%), including emulsification (6 eyes; 33.3%), epiretinal membrane (5 eyes; 27.8%), and posterior capsular opacification (4 eyes; 22.2%). Of the 14 eyes requiring intraoperative perfluorodecalin, 12 (85.7%) developed complications; all 5 (100%) eyes with direct exchange of perfluorodecalin with Oxane HD developed complications. CONCLUSION: Although useful for inferior retinal detachments, Oxane HD was associated with a relatively high rate of emulsification when compared to other series. Our series also suggests that prior use of perfluorodecalin intraoperatively, and in particular direct exchange of perfluorodecalin with Oxane HD, may be associated with an increased risk of intraocular complications.
BACKGROUND/AIMS: To assess the outcomes and complications of endotamponade with OxaneHD following retinal detachment repair. METHODS: Retrospective consecutive case series of inferior retinal detachment with OxaneHD endotamponade within a 3-year period. RESULTS: Case notes for 18 eyes of 18 patients were reviewed. Four (22.2%) were total retinal detachments and 13 (72.2%) had proliferative vitreoretinopathy. The mean OxaneHD endotamponade and follow-up durations were 27 ± 38 and 66 ± 39 weeks, respectively. The eventual anatomic success rate was 77.8%, but without any significant difference in vision. Postoperative complications occurred in 14 (77.8%), including emulsification (6 eyes; 33.3%), epiretinal membrane (5 eyes; 27.8%), and posterior capsular opacification (4 eyes; 22.2%). Of the 14 eyes requiring intraoperative perfluorodecalin, 12 (85.7%) developed complications; all 5 (100%) eyes with direct exchange of perfluorodecalin with OxaneHD developed complications. CONCLUSION: Although useful for inferior retinal detachments, OxaneHD was associated with a relatively high rate of emulsification when compared to other series. Our series also suggests that prior use of perfluorodecalin intraoperatively, and in particular direct exchange of perfluorodecalin with OxaneHD, may be associated with an increased risk of intraocular complications.
Authors: Francesco Morescalchi; Ciro Costagliola; Sarah Duse; Elena Gambicorti; Barbara Parolini; Barbara Arcidiacono; Mario R Romano; Francesco Semeraro Journal: Biomed Res Int Date: 2014-07-08 Impact factor: 3.411